Factors Affecting the Measurement of Cytokines in Biological Fluids: Implications for Their Clinical Measurement

Cohen S Pick E Oppenheim JJ . eds. Biology of the Lymphokines. New York: Academic Press, 1979.

Meager A. Cytokines. Milton Keynes: Open University Press, 1990.

Mizel SB . The interleukins. FASEB J 1989; 3: 2379–88.

Damas P Leroux D Nys M Vrindts Y de Groot D Franchimont P Cytokine serum levels during severe sepsis in human; IL-6 as a marker of severity. Ann Surg 1992; 215: 356–62.

Riikonen P Saarinen UM Teppo A-M Metsärinne K Fyhrquist F Jalanko H. Cytokine and acute phase reactant levels in serum of children with cancer admitted for fever and neutropenia. J Infect Dis 1992; 166: 432–6.

Duncombe AS Gottlieb DJ Bianiti A Brenner MK . Bioreactivity and immunoreactivity of tumour necrosis factor in cancer patients. Lancet 1988; i: 248.

Selby PJ Hobbs S Vino C Jackson E Smith IE McElwain TH . Endogenous tumour necrosis factor in cancer patients. Lancet 1988; i: 483.

Petersen CM Moller BK . Immunological reactivity and bioactivity of tumour necrosis factor. Lancet 1988; i: 934–5.

Balkwill F Osborne R Burke F Naylor S Talbot D Durbin H Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 1987; ii: 1229–32.

Mier JW Vachino C Van der Meer JWM Numerof RP Adams S Cannon JG Induction of circulating tumour necrosis factor (TNFα) on the mechanism of the febrile response to interleukin 2 (IL-2) in cancer patients. J Clin Immunol 1988; 8: 426–36.

Engleberts I Stephens S Francot GJM van der Linden CJ Buurman WA . Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; ii: 515–16.

Aderba D Engelmann H Hornik V Skornick Y Levo Y Wallach D Increased serum levels of soluble receptors for tumour necrosis factor in cancer patients. Cancer Res 1991; 51: 5602–7.

Helfgott DC Tatter SB Santhanam U Clarick RH Bhardwaj N May LT Multiple forms of IFN-β₂-/IL-6 in serum and body fluids during acute bacterial infections. J Immunol 1989; 142: 948–53.

May LT Viguet H Kenney JS Ida N Allison AC Sehgal PB . High levels of “complexed” interleukin-6 in human blood. J Biol Chem 1992; 267: 19698–704.

Wollenberg GK LaMarrec J Rosendal S Gonias SL Hayes AM . Binding of tumour necrosis factor alpha to activated forms of human plasma alpha 2 macroglobulins. Am J Pathol 1991; 138: 265–72.

Matsuda T Hirano T Nagasawa S Kishimoto T. Identification of α₂-macroglobulin as a carrier protein for IL-6. J Immunol 1989; 142: 148–52.

Hirano T Taga T Yamanalsi T Matsuda T Yasukawa K Hirata Y Molecular cloning of the cDNAs for Interleukin-6/B-cell stimulatory factor 2 and its receptor. Ann NY Acad Sci 1989; 557: 167–80.

May LT Santhanam U Tatter SB Ghrayeb J Sehgal PB . Multiple forms of human Interleukin-6. Ann NY Acad Sci 1989; 557: 114–21.

May LT Ghrayeb J Santhanam U Tatter SB Sthoeger Z Helfgott DC Synthesis and secretion of multiple forms of β₂-interferon/B-cell differentiation factor 2/hepatocyte stimulating factor by human fibroblasts and monocytes. J Biol Chem 1988; 263: 7760–6.

Weber TH Kiapyaho Kl Tanner P. Endogenous interference in immunoassays in clinical chemistry. A review. Scand J Clin Lab Invest 1990; 50 (suppl 201): 77–82.

Hamilton RG Whittington K Warner NB Arnett FC . Human IgM rheumatoid factor reactivity with rabbit, sheep, goat and mouse immunoglobulin. Clin Chem 1988; 4: 1165.

Thompson RJ Jackson AP Langbois N. Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects—incidence, species specificity and effects on a two-site assay for creatine kinase—MB isoenzyme. Clin Chem 1986; 32: 476–81.

Hamilton RG . Rheumatoid factor interference in immunological methods. Monogr Allergy 1989; 26: 27–44.

Bone RC . The pathogenesis of sepsis. Ann Int Med 1991; 115: 457–69.

Waage A Halstensen A Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i: 355–7.

Girardin E Grau GE Dayer J-M Roux-Lombard P Lambert PH . Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. New Eng J Med 1988; 319: 397–400.

De Groote MA Martin MA Densen P Pfaller MA Wenzel RP . Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 1989; 262: 249–51.

Debets JMH Kampmeijer R van der Linden MPMH Buurman WA van der Linden CJ . Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17: 489–94.

Damas P Reuter A Gysen P Demonty J Lamy M Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17: 975–8.

Marks JD Marks CB Luce JM Montgomery AB Turner J Metz CA Murray JF . Plasma tumor necrosis factor in patients with septic shock. Am Rev Respir Dis 1990; 41: 94–7.

Offner F Philippé J Vogelaers D Colardyn F Baele G Baudrihaye M Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 1990; 116: 100–5.

Cannon JG Tompkins RG Gelfand JA Michie HR Stanford GG Van Der Meer HWM Circulating interleukin-1 and tumor necrosis factor in septic and experimental endotoxin fever. J Infect Dis 1990; 161: 79–84.

Calandra T Baumgartner J-D Grau GE Wu MM Lambert P-H Schellekens J Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α and interferon-γ in the serum of patients with septic shock. J Infect Dis 1990; 161: 982–7.

Hyers TM Tricomi SM Dettenmeier PA Fowler AA . Tumor necrosis factor levels in serum and bronchoalveolar lavage fluid of patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1991; 144: 268–71.

Dofferhoff ASM Bom VJJ de Vries-Hospers HG van Ingen J vd Meer J Hazenberg BPC Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20: 185–92.

Sullivan JS Kilpatrick L Costarino AT Lee SC Harris MC . Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr 1992; 120: 510–15.

Members of the American College of Chest Physicians/Society of Critical Care Medicine Concensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Concensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864–74.

Seckinger P Isaaz S Dayer J-M. Purification and biological characterisation of a specific TNFα inhibitor. J Biol Chem 1989; 264: 11966–73.

Engelmann H Aderka D Rubinstein M Rotman D Wallach D. A tumor necrosis factor-binding protein purified to homogenicity from human urine protects cells from tumor necrosis factor. J Biol Chem 1989; 264: 11974–80.

Seckinger P Vey E Turcatti G Wingfield P Dayer J-M. Tumor necrosis factor inhibitor: Purification, NH2-terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities. Eur J Immunol 1990; 20: 1167–74.

Lesslauer W Tabuchi H Gentz R Brockhaus M Schlaeger EJ Grau G Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991; 21: 2883–6.

Van Zee KJ Kohono T Fisher E Rock CS Moldawer LL Lowry SF . Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845–9.

Foley N Lambert C McNicol M Johnson N Rook GAW . An inhibitor of the toxicity of tumour necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease. Clin Exp Immunol 1990; 80: 395–9.

Kalinkovich A Englemann H Harpaz N Burstein R Barak V Kalickman I Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol 1992; 89: 351–5.

Spinas GA Keller U Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992; 90: 533–6.

Girardin E Roux-Lombard P Grau GE Suter P Gallati H Dayer JM . Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992; 76: 20–3.

Symons JA Eastgate JA Duff GW . Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med 1991; 174: 1251–4.

Fanslow WC Sims JE Sassenfeld H Morrissey PJ Gilles S Dower SK Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990; 248: 739–42.

Granowitz EV Santos AA Poutisiaka DD Cannon JG Wilmore DW Wolff SM Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 1991; ii: 1423–4.

Wakabayashi G Gelfand JA Jung WK Connolly RJ Burke JF Dinnarello CA . Staphylococcus epidemidis induces complement activation, tumor necrosis and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. J Clin Invest 1991; 87: 1925–35.

Cannon JG Van der Meer JWM Kwiatkowski D Endres S Lonnemann G Burke JF Interleukin-1β in human plasma: Optimization of blood collection, plasma extraction, and radioimmunoassays methods. Lymphokine Res 1988; 7: 457–67.

Hopkins SJ Holt I Humphries M. Removal of inhibitory activity and determination of biologically active IL-1 in biological fluids. J Immunol Meth 1990; 133: 127–31.

Herzyk DJ Berger AE Allen JN Wewers MD . Sandwich ELISA formats designed to detect 17 kDa IL-1β significantly underestimate 35 kDa IL-1β. J Immunol Meth 1992; 148: 243–54.

Dinarello CA . ELISA kits based on monoclonal antibodies do not measure total IL-1β synthesis. J Immunol Meth 1992; 148: 255–9.

Dinarello CA . The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 1991; 163: 1177–84.

Waage A Brandtzaeg P Halstensen A Kierulf P Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169: 333–8.

Hack CE De Groot ER Felt-Bersma RJF Nuijens JH Van Schijndel RJM Strack Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704–10.

Calandra T Gerain J Heumann D Baumgarner J-D Glauser M. Swiss-Dutch J5 Immunoglobulin Study Group. High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1991; 91: 23–9.

Novick D Englemann H Wallach D. Purification of soluble cytokine receptors from normal urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr 1990; 510: 331–7.

Taga T Hibi M Hirata Y Yamasaki K Yasukawa K Matsuda T Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp 130. Cell 1989; 58: 573–81.

Heney D Novick D Lewis IJ Bailey CC Whicher J. Interleukin-6 (IL-6) and Soluble IL-6 Receptor; A study of their relationship with fever and neutrophil recovery in febrile neutropenia. Med Ped Onc 1992; 20: 376.

Nathan C Sporn M. Cytokines in context. J Cell Biol 1991; 113: 981–6.